• Publications
  • Influence
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
TLDR
Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. Expand
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
TLDR
Use of the new staging (IN RGSS) and risk classification (INRG) of neuroblastoma will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world. Expand
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
TLDR
By defining homogenous pretreatment patient cohorts, the INRG classification system will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world and the development of international collaborative studies. Expand
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
TLDR
Liposome formulations incorporating a synthetic polyethylene glycol-derivatized phospholipid can produce a large increase in the pharmacological efficacy of encapsulated antitumor drugs and have expanded considerably the prospects of liposomes as an effective carrier system for a variety of pharmacologically active macromolecules. Expand
The International Neuroblastoma Pathology Classification (the Shimada system)
The International Neuroblastoma Pathology Committee, which is comprised of six member pathologists, was convened with the objective of proposing a prognostically significant and biologically relevantExpand
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.
TLDR
Treatment with myeloablative therapy and autologous bone marrow transplantation improved event-free survival among children with high-risk neuroblastoma, and treatment with 13-cis-retinoic acid was beneficial for patients without progressive disease when it was administered after chemotherapy or transplantation. Expand
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
TLDR
The long-term outcome of patients enrolled on CCG-3891, a high-risk neuroblastoma study in which patients were randomly assigned to undergo autologous purged bone marrow transplantation or to receive chemotherapy, and subsequent treatment with 13-cis-retinoic acid (Cis-RA), was assessed. Expand
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
TLDR
Heterogeneous pretreatment patient cohorts have been defined by the International Neuroblastoma Risk Group classification system and led to advances in understanding of neuroblastoma biology, refinements in risk classification, and stratified treatment strategies, resulting in improved outcome. Expand
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project.
TLDR
The present consensus report was written by the INRG Imaging Committee to optimize imaging and staging and reduce interobserver variability and contribute substantially to more uniform staging and thereby facilitate comparisons of clinical trials conducted in different parts of the world. Expand
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
TLDR
The results show the importance of Mycn as a therapeutic target in established tumors in vivo, offer a mechanistic rationale to test PI3K inhibitors in MYCN-amplified neuroblastoma, and represent a therapeutic approach applicable to a broad range of cancers in which transcription factors are stabilized through aPI3K-dependent mechanism. Expand
...
1
2
3
4
5
...